Physician profile
Charles L Bane
NPI 1730134933
$12,963.90
in general payments reported to CMS, 2019-2025
80 companies · $3,289 in 2025
The $3,289 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $172 · 2021: $441 · 2022: $1,364 · 2023: $3,511 · 2024: $3,061 · 2025: $3,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,818 · Education: $42.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,818.03 |
| Education | $42.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,055.58 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $928.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $782.48 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $660.40 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $632.20 | 2023-2025 | Epkinly |
| Genentech USA, INC. | $535.98 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Pharmacyclics LLC, An Abbvie Company | $475.71 | 2019-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $470.49 | 2021-2025 | Cabometyx |
| Incyte Corporation | $469.12 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $428.01 | 2019-2025 | |
| Daiichi Sankyo INC. | $416.60 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $412.53 | 2019-2025 | |
| Tersera Therapeutics LLC | $353.14 | 2021-2025 | Zoladex, Xermelo |
| Lilly USA, LLC | $277.61 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $276.67 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $252.20 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $234.46 | 2022-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $224.86 | 2020-2025 | Onivyde |
| E.R. Squibb & Sons, L.L.C. | $211.29 | 2019-2025 | Opdivo, Opdualag |
| Stemline Therapeutics INC. | $205.42 | 2023-2025 | Orserdu, Elzonris |
| Amgen INC. | $203.58 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Gilead Sciences, INC. | $194.19 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $165.30 | 2020-2024 | Fruzaqla, Iclusig, Alunbrig |
| Eisai INC. | $163.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $153.57 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Adc Therapeutics America, INC. | $149.76 | 2023-2025 | |
| Varian Medical Systems, INC. | $140.88 | 2019-2020 | |
| Astellas Pharma US INC | $139.89 | 2019-2024 | Xtandi, Xospata |
| Beigene USA, INC. | $132.69 | 2022-2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $132.54 | 2019-2025 | Zepzelca |
| Array Biopharma INC | $107.29 | 2019-2024 | Braftovi, Mektovi, Xalkori |
| Sobi, INC | $106.15 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $97.10 | 2024-2025 | |
| Genmab U.S., INC. | $95.21 | 2022-2024 | Epkinly |
| Adaptive Biotechnologies Corporation | $90.59 | 2023-2025 | Clonoseq |
| Foundation Medicine, INC. | $82.62 | 2019-2023 | |
| Pharmaessentia USA Corporation | $80.93 | 2023-2024 | Besremi |
| Seagen INC. | $78.79 | 2022-2023 | Padcev, Tukysa |
| Rigel Pharmaceuticals, INC. | $75.09 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Kyowa Kirin, INC. | $72.89 | 2023-2024 | Poteligeo |
| Syndax Pharmaceuticals, INC. | $71.33 | 2025 | Revuforj |
| Beone Medicines USA, INC. | $69.56 | 2025 | Tevimbra, Brukinsa |
| Blueprint Medicines Corporation | $67.77 | 2023-2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $64.37 | 2023-2025 | Qinlock, Romvimza |
| Alexion Pharmaceuticals, INC. | $61.09 | 2023-2025 | Ultomiris |
| Kite Pharma, INC. | $56.90 | 2021-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $56.52 | 2023-2024 | |
| Legend Biotech USA INC. | $54.46 | 2024-2025 | Carvykti |
| Karyopharm Therapeutics INC. | $52.11 | 2022-2024 | Xpovio |
| Cardinal Health 110 LLC | $48.81 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $44.29 | 2023-2025 | Sancuso |
| Apellis Pharmaceuticals, INC. | $40.06 | 2023 | Empaveli |
| Springworks Therapeutics, INC. | $38.53 | 2025 | Ogsiveo |
| Taiho Oncology, INC. | $35.55 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $32.02 | 2022-2025 | Pyrukynd |
| Aurobindo Pharma USA, INC. | $31.94 | 2019 | |
| Puma Biotechnology, INC. | $28.23 | 2019 | |
| Clovis Oncology, INC. | $25.76 | 2019 | |
| Progenics Pharmaceuticals, INC. | $25.02 | 2025 | |
| Morphosys, US INC. | $24.52 | 2023 | Monjuvi |
| Tempus Ai, INC | $24.17 | 2025 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $24.15 | 2019 | |
| Emd Serono, INC. | $21.42 | 2025 | |
| Recordati_rare_diseases_inc. | $21.08 | 2023 | Sylvant |
| Alnylam Pharmaceuticals INC. | $20.84 | 2022 | |
| Eusa Pharma (US) LLC | $20.06 | 2019 | |
| Iovance Biotherapeutics, INC. | $16.80 | 2025 | Amtagvi |
| Immunocore Limited | $16.77 | 2024 | Kimmtrak |
| Dendreon Pharmaceuticals LLC | $16.05 | 2024 | Provenge |
| Myriad Genetic Laboratories, INC. | $15.87 | 2024 | Myrisk |
| Sirtex Medical INC | $15.79 | 2024 | Sir-Spheres Microspheres |
| G1 Therapeutics, INC. | $15.04 | 2022 | |
| Heron Therapeutics, INC. | $14.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.52 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.30 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.